e-learning
resources
Amsterdam 2011
Sunday, 25.09.2011
Rare diffuse lung diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Baseline characteristics of an Italian cohort of pulmonary alveolar proteinosis (PAP) patients
I. Campo, Z. Kadija, F. Mariani, G. Rodi, E. Paracchini, C. Chalk, B. C. Trapnell, M. Luisetti (Pavia, Italy; Cincinnati, United States Of America)
Source:
Annual Congress 2011 - Rare diffuse lung diseases
Session:
Rare diffuse lung diseases
Session type:
Thematic Poster Session
Number:
630
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. Campo, Z. Kadija, F. Mariani, G. Rodi, E. Paracchini, C. Chalk, B. C. Trapnell, M. Luisetti (Pavia, Italy; Cincinnati, United States Of America). Baseline characteristics of an Italian cohort of pulmonary alveolar proteinosis (PAP) patients. Eur Respir J 2011; 38: Suppl. 55, 630
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: What’s NEW in the 2022 ERS/ATS PFT Interpretation Statement
Late Breaking Abstract - Efficacy of Breathox® device inhalation on acute symptoms associated with COVID-19 (BREATH study)
Lane-hamilton syndrome and CCF: a fatal association
Related content which might interest you:
Baseline characteristics of the Italian cohort of patients affected by pulmonary alveolar proteinosis (PAP)
Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease
Year: 2008
Clinical features of autoimmune pulmonary alveolar proteinosis from a large international patient cohort: baseline data from the IMPALA trial
Source: International Congress 2019 – Rare and ultra-rare diseases and the lungs: updates and new perspectives
Year: 2019
Pulmonary alveolar proteinosis, study of 29 cases
Source: Annual Congress 2010 - Rare diffuse lung diseases
Year: 2010
Long term follow-up in patients with pulmonary alveolar proteinosis
Source: Annual Congress 2011 - Rare diffuse lung diseases
Year: 2011
Pulmonary alveolar proteinosis (PAP) - clinical features and response to treatment by bronchofiberoscopic lobar lavage
Source: Eur Respir J 2005; 26: Suppl. 49, 541s
Year: 2005
Serum SP-A as predictor of disease progression in patients with pulmonary alveolar proteinosis
Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities
Year: 2012
Baseline characteristics and survival of patients with idiopathic pulmonary fibrosis (IPF): analysis from the Swedish IPF registry
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020
Clinical assessment and management of pulmonary alveolar proteinosis: the importance of a reference centre
Source: Annual Congress 2009 - Pulmonary alveolar proteinosis: clearing the Milky Way
Year: 2009
Determinants of protein concentration in whole lung lavage of patients with pulmonary alveolar proteinosis
Source: Annual Congress 2009 - From genetics to clinics in diffuse parenchymal lung diseases
Year: 2009
Whole lung lavage (WLL) in pulmonary alveolar proteinosis (PAP): long-term lung function follow-up
Source: Eur Respir J 2001; 18: Suppl. 33, 220s
Year: 2001
Analysis of baseline characteristics by emphysema extent in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017
Our cases with pulmonary alveolar proteinosis
Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs)
Year: 2018
Association of pulmonary alveolar proteinosis and fibrosis: patient with GATA2 deficiency
Source: Eur Respir J 2016; 48: 1510-1514
Year: 2016
Longitudinal observation of idiopathic pulmonary fibrosis (IPF) patients cohort from one center in Poland.
Source: International Congress 2019 – Interstitial lung disease registries
Year: 2019
Whole lung lavage therapy (WLL) of pulmonary alveolar proteinosis (PAP): A global survey of current practices and procedures
Source: International Congress 2016 – Orphan diseases I
Year: 2016
Whole lung lavage (WLL) for patients with pulmonary alveolar proteinosis
Source: Eur Respir J 2004; 24: Suppl. 48, 670s
Year: 2004
Clinical features of secondary pulmonary alveolar proteinosis: pre-mortem cases in Japan
Source: Eur Respir J 2011; 37: 465
Year: 2011
Peculiarities of pulmonary alveolar proteinosis (PAP) due to exogenous factors
Source: Virtual Congress 2020 – Occupational exposure as a cause of respiratory disease
Year: 2020
Pulmonary alveolar proteinosis (PAP) in exogenous toxic alveolitis (ETA) patients
Source: International Congress 2015 – Occupational disease: clinical cases and series
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept